Chronic Lower Back Pain Treatment Market Size (7MM) was ~ USD 6,071 million in 2023 and It is projected to grow at a CAGR of 3.7% by 2034, estimates DelveInsight

DelveInsight's 'Chronic Lower Back Pain Market Insights, Epidemiology, and Market Forecast-2034' report delivers an in-depth understanding of the Chronic Lower Back Pain, historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

Key Takeaways from the Chronic Lower Back Pain Market Report
• The total diagnosed prevalent cases of CLBP in the United States were around 31 million cases in 2023.
• The United States contributed to the largest diagnosed prevalent population of CLBP, acquiring ~45% of the 7MM in 2023. Whereas, EU4 and the UK, and Japan accounted for around 40% and 15% of the total population share, respectively, in 2023.
• Among the EU4 countries, Spain accounted for the largest number of Prevalent CLBP (8.6 million) cases followed by Germany (6.3 million), whereas France accounted for the lowest number of cases (5 million) in 2023.
• In 2023, it was estimated that there were around 8 million diagnosed cases in the age group of 70 years and older in the US.
• According to DelveInsight estimates, in 2023 there were approximately 5.5 million diagnosed prevalent cases of chronic low back pain (CLBP) among males and about 4.5 million cases among females in Japan.
• DelveInsight analysis of the age-specific data in the US revealed that the highest number of people affected with CLBP were found in the age group of 70+ years, while people who belonged to the age group 60-69 years were the least affected.
• The leading Chronic Lower Back Pain Companies working in the market include Eli Lilly and Company, Collegium Pharmaceutical, Purdue Pharma LP, BioDelivery Sciences International, Camurus, Braeburn Inc., Scilex Holding, Mesoblast Limited, AnGes MG, Inc., Kolon Life Science, Eliem Therapeutics, Allodynic Therapeutics, Sollis Therapeutics, Medtronic Spinal and Biologics, Frontier Biotechnologies, DiscGenics Inc., Pfizer, Persica Pharmaceuticals, BioRestorative Therapies, Vertanical GmbH, Stayble Therapeutics, SpineThera, and others.
• Promising Chronic Lower Back Pain Pipeline Therapies in the various stages of development include Buprenorphine, Bupivacaine TTS (Bupivacaine Patch), Duloxetine, AB001 patch, Bicifadine, DRX9000, and others.

Discover which therapies are expected to grab the Chronic Lower Back Pain Market Share @ Chronic Lower Back Pain Market Outlook- https://www.delveinsight.com/sample-request/chronic-lower-back-pain-clbp-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Chronic Lower Back Pain Overview
Chronic lower back pain is a long-standing and persistent pain located in the lower back region, which is below the ribcage. This type of pain is categorized as "chronic" when it lasts for more than 12 weeks, even after an initial injury or underlying cause of acute lower back pain has been treated.

Chronic Lower Back Pain Epidemiology Insights
• Chronic Lower Back Pain Total Incident Cases
• Age-specific Chronic Lower Back Pain cases
• Gender-specific Chronic Lower Back Pain Cases
• Stage-specific Chronic Lower Back Pain incident cases
• Type-specific Chronic Lower Back Pain incident cases
• Total Treated Chronic Lower Back Pain Cases

Download the report to understand which factors are driving Chronic Lower Back Pain Epidemiology trends @ Chronic Lower Back Pain Epidemiological Insights- https://www.delveinsight.com/sample-request/chronic-lower-back-pain-clbp-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Chronic Lower Back Pain Marketed Drugs
• XTAMPZA ER (oxycodone): Collegium Pharmaceutical
XTAMPZA ER (oxycodone) is a semisynthetic opioid. It is currently indicated as an immediate-release product for moderate-to-severe pain and as an extended-release product for chronic moderate-to-severe pain requiring continuous opioid analgesics for an extended period. It is used to manage acute and chronic pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Oxycodone is a highly selective full agonist of the μ-opioid receptor (MOR), with low affinity for the d-opioid receptor (DOR) and ?-opioid receptor (KOR). Oxycodone and its active metabolites can selectively bind to the μ-opioid receptor and the kappa and delta-opioid receptors in the central nervous system and periphery and induce a G protein-coupled receptor signaling pathway.

Chronic Lower Back Pain Emerging Drugs
• Rexlemestrocel-L (MPC-06-ID): Mesoblast Limited/Grünenthal
Rexlemestrocel-L, also known as MPC-06-ID, is a Mesoblast's proprietary allogeneic mesenchymal precursor cell (MPC) product candidate, currently in the late stage of development for the treatment of CLBP caused by disc degeneration. It is being developed for patients who have exhausted conservative treatment options, may have failed epidural steroid injections, and have no further treatment option other than invasive and costly surgical interventions.

• Semdexa (SP-102): Scilex Holding Company
Semdexa (SP-102, dexamethasone sodium phosphate) is a non-opioid corticosteroid formulated as a viscous gel injection that is under development to treat lumbar radicular pain/sciatica, containing no neurotoxic preservatives, surfactants, solvents, or particulates. Because of these properties, the drug is expected to have a better safety profile than commonly used off-label injected corticosteroids. SP-102 has an ingredient that is a widely used corticosteroid solution.

To know more about Chronic Lower Back Pain treatment guidelines, visit @ Chronic Lower Back Pain Treatment Market Landscape- https://www.delveinsight.com/sample-request/chronic-lower-back-pain-clbp-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Chronic Lower Back Pain Market Outlook
CLBP is a complex process comparable to how each patient has a very individualized disease process the treatment regimen is similarly individualized. There are several different medication classes, each with an exclusive mechanism of action that can help the practitioner target a specific aspect of a patient's pain. Moreover, patient-specific factors are considered when developing a regimen to ensure adherence and improve outcomes. Most (80-90%) of low back pain cases stem from a mechanical origin, such as degenerative disc or joint disease, vertebral fractures, and deformities. Neurogenic, inflammatory, and other less common causes comprise the remaining etiologies. The initial pharmacological agents chosen should align with the underlying etiology. However, as pain transitions to a chronic state, a more comprehensive approach is often necessary due to the reduced efficacy of targeted treatments.

Chronic Lower Back Pain Drugs Uptake
The drug chapter of the Chronic Lower Back Pain report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to Chronic Lower Back Pain.

Major Chronic Lower Back Pain Companies
Several Chronic Lower Back Pain Companies working in the market include Eli Lilly and Company, Collegium Pharmaceutical, Purdue Pharma LP, BioDelivery Sciences International, Camurus, Braeburn Inc., Scilex Holding, Mesoblast Limited, AnGes MG, Inc., Kolon Life Science, Eliem Therapeutics, Allodynic Therapeutics, Sollis Therapeutics, Medtronic Spinal and Biologics, Frontier Biotechnologies, DiscGenics Inc., Pfizer, Persica Pharmaceuticals, BioRestorative Therapies, Vertanical GmbH, Stayble Therapeutics, SpineThera, and others.

Learn more about the FDA-approved drugs for Chronic Lower Back Pain @ Drugs for Chronic Lower Back Pain Treatment- https://www.delveinsight.com/sample-request/chronic-lower-back-pain-clbp-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Chronic Lower Back Pain Market Research Report
• Coverage- 7MM
• Study Period- 2020-2034
• Chronic Lower Back Pain Companies- Eli Lilly and Company, Collegium Pharmaceutical, Purdue Pharma LP, BioDelivery Sciences International, Camurus, Braeburn Inc., Scilex Holding, Mesoblast Limited, AnGes MG, Inc., Kolon Life Science, Eliem Therapeutics, Allodynic Therapeutics, Sollis Therapeutics, Medtronic Spinal and Biologics, Frontier Biotechnologies, DiscGenics Inc., Pfizer, Persica Pharmaceuticals, BioRestorative Therapies, Vertanical GmbH, Stayble Therapeutics, SpineThera, and others.
• Chronic Lower Back Pain Pipeline Therapies- Buprenorphine, Bupivacaine TTS (Bupivacaine Patch), Duloxetine, AB001 patch, Bicifadine, DRX9000, and others.
• Chronic Lower Back Pain Market Dynamics: Chronic Lower Back Pain Market Drivers and Barriers
• Chronic Lower Back Pain Market Access and Reimbursement, Unmet Needs and Future Perspectives

Discover more about Chronic Lower Back Pain Drugs in development @ Chronic Lower Back Pain Clinical Trials Assessment- https://www.delveinsight.com/sample-request/chronic-lower-back-pain-clbp-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Report Introduction
3. Chronic Lower Back Pain Market Overview at a Glance
4. Executive Summary of Chronic lower back pain (CLBP)
5. Key Events
6. Chronic Lower Back Pain (CLBP): Disease Background and Overview
7. Epidemiology and Patient Population
8. Patient Journey
9. CLBP Marketed Therapies
10. Emerging Therapies
11. Failed therapies
12. Chronic Lower Back Pain: Seven Major Market Analysis
13. KOL Views
14. CLBP Market Drivers
15. CLBP Market Barriers
16. SWOT Analysis
17. Unmet Needs
18. CLBP Market Access and Reimbursement
19. Appendix
20. DelveInsight Capabilities
21. Disclaimer

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.